Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

Bressler, Brian; Marshall, John K.; Bernstein, Çharles N.; Bitton, Alain; Jones, Jennifer; Leontiadis, Grigorios I; Panaccione, Remo; Steinhart, A. Hillary; Tse, Francis L. S.; Feagan, Brian G.; Afif, Waqqas; Bernard, Edmond-Jean; Borgaonkar, Mark; Devlin, Shane; Fedorak, Richard N.; Nguyen, Geoffrey C.; Penner, Robert; Peyrin–Biroulet, Laurent; Reinisch, Walter; Seow, Cynthia H.; Sy, Richmond; Targownik, Laura E.; Thomson, Peter; Assche, Gert Van; Cn, Williams

doi:10.1053/j.gastro.2015.03.001

Cited by 362 publications

(291 citation statements)

References 164 publications

(320 reference statements)

Supporting

Mentioning

268

Contrasting

Unclassified

Order By: Relevance

“…UC cases without treatment or with inadequate treatment may evolve with some complications like need of colectomy or colon tumors [26,27]. The follow-up of these patients should be regular and the medication maintained in the long term [28].…”

Section: Discussionmentioning

confidence: 99%

Turner Syndrome and Inflammatory Bowel Disease: Case Report

Reis¹,

Castro²,

Vieira³

et al. 2018

JPP

View full text Add to dashboard Cite

Summary: TS (Turner syndrome) is a genetic disease which affects women caused by complete or partial absence of one of the X chromosomes. This condition is related to an increase in autoimmune diseases incidence like, IBD (inflammatory bowel disease). Material and Methods: a case report of a 31 years old woman with TS hospitalized with two months of prostration, fever, rashes, nausea, vomit and diarrhea. Investigations have shown colonic mucosa inflammation, besides chronic colitis with cryptic microabscess in the anatomopathological evaluation, suggesting IBD as etiology. Treatment with mesalazine was effective in symptoms improvement. Conclusions: TS is a condition frequently associated with autoimmune diseases, including diseases of the gastrointestinal tract, such as IBDs. Recognition and early treatment of this condition leads to an improvement in the quality of life of these patients and reduces the chances of future complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Turner Syndrome and Inflammatory Bowel Disease: Case Report

Reis¹,

Castro²,

Vieira³

et al. 2018

JPP

View full text Add to dashboard Cite

show abstract

“…The choice of testing a specific probiotic blend (acronelle ® , Bromatech srl, milan, italy) was suggested by the distinguishing features of the bacterial strains contained in the considered probiotic blend: lactobacillus salivarius has a high anti-inflammatory and antibacterial activity, especially against some of those pathogenic bacterial strains, usually present on the intestinal mucosa of iBd patients 27 ; Bifidobacterium bifidum BGN 4 supports lactobacilli against inflammation, thanks to the chiro-inositol present in its cell membrane, which seems to reduce the production of pro-inflammatory cytokines 28 . although guidelines 29 suggest to treat moderate-to-severe Uc with corticosteroids, the contemporary use of mesavancol® and acronelle® allowed to reach an encouraging result, avoiding all those therapy side effects which usually decrease patient compliance. For the first time, the long-term efficacy (2 years) of such a probiotic blend has been proven, also demonstrating the synergistic effect on disease activity, especially when coupled with anti-inflammatory treatment.…”

Section: Discussionmentioning

confidence: 99%

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Palumbo¹,

Romeo²,

Gammazza³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

100

View full text Add to dashboard Cite

Aim.Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

show abstract

“…The clinical practice guidelines from the Toronto UC consensus group also indicated that in patients with an inadequate response to initial anti-TNF therapy, it is important to consider dose intensification before deciding on alternative treatments [36] because patients with higher serum anti-TNF concentrations have a higher probability of induction and maintenance of complete clinical and endoscopic remission [37,38]. Although it seems that anti-TNFa treatments have a better clinical outcome than calcineurin inhibitors, it should be emphasized that secondary loss of responsiveness to anti-TNFa treatments is often observed.…”

Section: Anti-tnfa Treatmentmentioning

confidence: 99%

Recent trends and future directions for the medical treatment of ulcerative colitis

Mizuno

Nanki

Sugimoto

et al. 2016

Clin J Gastroenterol

View full text Add to dashboard Cite

Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) a treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to antiTNFa treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

show abstract

Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus

Cited by 362 publications

References 164 publications

Turner Syndrome and Inflammatory Bowel Disease: Case Report

Turner Syndrome and Inflammatory Bowel Disease: Case Report

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Recent trends and future directions for the medical treatment of ulcerative colitis

Contact Info

Product

Resources

About